Palvella Therapeutics (PVLA) Shareholder's Equity Growth (3y) (2016 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Palvella Therapeutics | 1.47 Bn | 1.21 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 146.78% |
| Dec 31, 2025 | 31.97% |
| Jun 30, 2025 | 2.50% |
| Mar 31, 2025 | 1.31% |
| Dec 31, 2024 | 7.25% |
| Sep 30, 2024 | -53.59% |
| Jun 30, 2024 | -55.09% |
| Mar 31, 2024 | -58.88% |
| Dec 31, 2023 | -63.87% |
| Sep 30, 2023 | -11.28% |
| Jun 30, 2023 | -4.62% |
| Mar 31, 2023 | -32.29% |
| Dec 31, 2022 | -56.41% |
| Jun 30, 2022 | 31.56% |
| Mar 31, 2022 | 21.01% |
| Dec 31, 2021 | 8.32% |
| Sep 30, 2021 | 2.33% |
| Jun 30, 2021 | -5.47% |
| Mar 31, 2021 | -8.97% |
| Dec 31, 2020 | 39.12% |
| Sep 30, 2020 | 112.42% |
| Jun 30, 2020 | 71.00% |
| Mar 31, 2020 | 40.30% |
| Dec 31, 2019 | 26.74% |
| Sep 30, 2019 | -13.13% |
| Jun 30, 2019 | -19.46% |
| Mar 31, 2019 | 3.54% |
| Dec 31, 2018 | 8.66% |
| Sep 30, 2018 | 14.31% |
| Jun 30, 2018 | 70.57% |
| Mar 31, 2018 | 52.73% |
| Dec 31, 2017 | -13.83% |
| Sep 30, 2017 | 1,615.01% |
| Jun 30, 2017 | 876.83% |
| Mar 31, 2017 | 1,457.30% |
| Dec 31, 2016 | 250.67% |
| Jun 30, 2016 | 1,890.85% |